Thomas Flaig, MD, discusses the study of abiraterone acetate in metastatic prostate cancer after hormone induction failure and its impact on future research in this setting.
Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer.
Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.
As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.
The FDA has granted an accelerated approval to atezolizumab as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer.
The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.
The US Preventive Services Task Force may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.
Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.